Research Article
Potential of IL-33 for Preventing the Kidney Injury via Regulating the Lipid Metabolism in Gout Patients
Table 1
Demographic data and clinical characteristics of subjects in the study.
| | Characteristics | Gout patients | Healthy control |
| | Total | 41 | 44 | | Male sex | 39 (95%) | 41 (93%) | | Age at study mean (SD) years | 58.3 (15.55) | 56.8 (17.91) | | Course of disease, mean (range) years | 10.6 (0.3–40) | — | | Clinical manifestation, (%) | | | | Hyperuricemia | 27 (65.8%) | — | | Acute phase | 36 (87%) | — | | Tophi | 15 (36.5%) | — | | Gouty kidney damage | 13 (31.7%) | — | | Hypercholesteremia | 18 (43.9%) | — | | Hypertension | 21 (51.2%) | — | | Osteoporosis | 19 (46.3%) | — | | Fever | 4 (9.7%) | — |
|
|
